Natera

CancerIQ Adds Dr. Jeffrey Weitzel, MD as Strategic Advisor

Retrieved on: 
星期四, 十二月 21, 2023
Natera, Partnership, Risk, Division, Research, Breast Cancer Research Foundation, Cancer Moonshot, City, NCCN, MD, Society, Panel, Education, Cancer, Genetics, Genomics, University, Breast cancer, Genetic testing, Patient, Diagnosis, American School, FACP, Pharmaceutical industry

CHICAGO, Dec. 21, 2023 /PRNewswire-PRWeb/ -- CancerIQ, the platform powering early cancer detection and prevention across broad patient populations, announced today that Jeffrey Weitzel, MD, cofounder of the City of Hope Clinical Cancer Genomics Community of Practice, was named an official strategic advisor to the company. In this role, Dr. Weitzel's deep, cross-sector expertise will help inform research and product development and enrich CancerIQ's longstanding commitment to mainstreaming cancer genetics as part of routine care.

Key Points: 
  • CHICAGO, Dec. 21, 2023 /PRNewswire-PRWeb/ -- CancerIQ, the platform powering early cancer detection and prevention across broad patient populations, announced today that Jeffrey Weitzel, MD, cofounder of the City of Hope Clinical Cancer Genomics Community of Practice, was named an official strategic advisor to the company.
  • "As a strategic advisor to CancerIQ, I look forward to driving continued innovation in this space."
  • As a strategic advisor, Dr. Weitzel will work with CancerIQ to advance translational research in the delivery of cancer genetics and genomics.
  • "As a strategic advisor to CancerIQ, I look forward to driving continued innovation in this space."

Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents

Retrieved on: 
星期一, 十二月 11, 2023
Oncology, Health, Biometrics, Genetics, Other Health, Research, Science, NTRA, DNA, Court, District court, Natera

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware has issued an order denying CareDx’s motion for summary judgment on two Natera patents in the infringement lawsuit filed by Natera against CareDx.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware has issued an order denying CareDx’s motion for summary judgment on two Natera patents in the infringement lawsuit filed by Natera against CareDx.
  • The Court has ruled that two of the patents asserted by Natera against CareDx will proceed to trial.
  • The trial will commence on January 22, 2024.
  • As previously disclosed , Natera successfully invalidated all three of CareDx’s patents that were asserted against Natera in a related case.

Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

Retrieved on: 
星期三, 十二月 6, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Circulating tumor DNA, FACP, DNA, Neoplasm, DARE, Risk, Breast cancer, NTRA, Patient, Monarch butterfly migration, MRD, Single-camera setup, Abstract, MD, Doctor of Philosophy, Recurrence, Medical imaging, Vaccine, Natera, HR

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2023 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2023 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.
  • The presentations feature tumor-informed MRD data spanning the neoadjuvant, adjuvant, surveillance, and metastatic treatment settings, including analyses from the DARE, monarchE, and LEADER trials in HR+/HER2- breast cancer.
  • “We are excited to showcase our leadership at SABCS with thought-provoking new data that demonstrate our commitment to personalizing patient care across the breast cancer continuum,” said Minetta Liu, MD, chief medical officer of oncology, at Natera.
  • Additionally, none of the patients developed recurrence if they were initially ctDNA-positive and later became ctDNA-negative during treatment (ctDNA clearance).

Braving New Frontiers in Cancer Monitoring - Learn Look Locate (LLL) Hosts Educational Natera™ Site for Personalized Signatera™ Tests

Retrieved on: 
星期一, 十二月 11, 2023
Empowerment, Woman, DNA, LLL, Medical director, Neoplasm, Breast cancer, Patient, Natera, MRD, Genetic testing, Cancer, Diagnosis, Breast reconstruction, Aftercare, Recurrence, Knowledge, Education, Vaccine, Medical imaging, Mammography

TUCSON, Ariz., Dec. 11, 2023 /PRNewswire/ -- Following a previous collaboration with Natera, a global cell-free DNA testing leader, LLL announced that it would host a dedicated webpage,  for Natera's revolutionary molecular residual disease assay (MRD) test: Signatera. MRD is used to describe the small amount of residual cancer cells that patients retain after cancer treatment and is used as a major predictor of relapse. The new LLL page will highlight the benefits of Signatera, while also giving patients and readers access to LLL's vast archive of breast cancer resources.

Key Points: 
  • The Signatera MRD assay can detect cancer recurrence far earlier than conventional methods by monitoring circulating tumor DNA (ctDNA).
  • "Signatera takes cancer management to a whole new level," said Dr. Barry Rosen, Senior Medical Advisor for LLL.
  • Dedicated to fostering inclusive education on breast health and cancer, Learn Look Locate passionately delivers the latest advancements, ensuring every individual is empowered with knowledge.
  • Cynthia's journey fuels our mission, ensuring no one feels as scared and uneducated as she did during her breast cancer diagnosis.

Natera Reports Third Quarter 2023 Financial Results

Retrieved on: 
星期三, 十一月 8, 2023
Medical Devices, Women, Genetics, Health Technology, General Health, Consumer, Health, Science, Oncology, Other Science, Tracker, Growth, III, Medicare, SOFR, Colorectal cancer, Foundation Medicine, GAAP, NTRA, Research, Chronic kidney disease, Partnership, UBS, Credit line, Investment, Patient, DNA, Video game, Film industry, Pharmaceutical industry, Natera

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2023.
  • Delivered gross margin of 45.1% in the third quarter of 2023, compared to 44.7% in the third quarter of 2022.
  • Reduced cash burn to approximately $38 million in the third quarter of 2023, a decrease of approximately 66% compared to the third quarter of 2022.
  • Processed approximately 626,000 tests in the third quarter of 2023, compared to approximately 517,500 tests in the third quarter of 2022, an increase of approximately 21%.

Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

Retrieved on: 
星期三, 十一月 8, 2023
Research, Genetics, Clinical Trials, Biometrics, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, European Organisation for Research and Treatment of Cancer, Patient, III, SERD, Treatment, EORTC, Menarini, NTRA, Circulating tumor DNA, MRD, Recurrence, Breast cancer, Neoplasm, Death, DNA, Medical imaging, Natera, Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be used in a new breast cancer study called TREAT ctDNA (EORTC 2129-BCG).

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be used in a new breast cancer study called TREAT ctDNA (EORTC 2129-BCG).
  • This international, multi-center, randomized, phase III clinical trial is being conducted by the European Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Group in collaboration with Natera and Menarini Group (Menarini), a leading international pharmaceutical and diagnostics company.
  • “We are excited to offer to our high-risk, ctDNA positive, ER+/HER2- early-stage breast cancer patients the possibility to participate in the TREAT ctDNA trial.
  • “Collaborations with leading clinical trial organizations like EORTC are needed as we seek to demonstrate the power of treatment on molecular recurrence across cancer indications.

Personalis Reports Third Quarter 2023 Financial Results

Retrieved on: 
星期二, 十一月 7, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Medicare, Lung cancer, Genomics, Breast cancer, PSNL, NeXT, Investment, VA, Pharmaceutical industry, Video game, Cryptocurrency, Beauty salon, Natera, Chief Justice of Hungary

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2023 and provided recent business highlights.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2023 and provided recent business highlights.
  • The conference call can be accessed live by dialing 844-826-3035 for domestic callers or 412-317-5195 for international callers.
  • The live webinar can be accessed at https://investors.personalis.com .
  • A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

Natera to Participate in November Investor Conferences

Retrieved on: 
星期二, 十一月 7, 2023
Oncology, Health, FDA, Genetics, Other Health, Clinical Trials, Biotechnology, DNA, NTRA, Natera

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in November.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in November.
  • Tuesday, Nov. 14 at 12:00 pm ET | 9:00 am PT in Nashville, TN
    Tuesday, Nov. 28 at 2:30 pm ET | 11:30 am PT in New York, NY
    A live webcast and audio archive of each event may be accessed through the investor relations section of the Natera website at investor.natera.com .
  • Replays of the events will be available shortly following the conferences.

NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA

Retrieved on: 
星期六, 十一月 4, 2023
Class Action Lawsuit, Professional Services, Legal, Oportunidades, KSF, NTRA, Marketing, Natera

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Natera, Inc. (NasdaqGS: NTRA).

Key Points: 
  • Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Natera, Inc. (NasdaqGS: NTRA).
  • Recently, the court presiding over that case denied the Company’s motion to dismiss in part, allowing the case to move forward.
  • KSF’s investigation is focusing on whether Natera’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms.

Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations

Retrieved on: 
星期四, 十月 26, 2023
Laboratory, Colorectal cancer, Commercial Operating System, Entrepreneurship, Growth, CRC, Business, Cancer, Video game, Natera, DACH

BERKELEY, Calif. and MAINZ, Germany, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is proud to announce the appointment of Tarrin Khairi-Taraki as Vice President of Commercial Operations, EMEA. Tarrin will play a pivotal role in steering Mainz Biomed's continued success, focusing on the commercialization of its flagship product, ColoAlert® — a highly effective and user-friendly at-home detection test for colorectal cancer (CRC).

Key Points: 
  • Tarrin will play a pivotal role in steering Mainz Biomed's continued success, focusing on the commercialization of its flagship product, ColoAlert® — a highly effective and user-friendly at-home detection test for colorectal cancer (CRC).
  • "I am thrilled to welcome Tarrin to the Mainz Biomed team," commented Darin Leigh, Chief Commercial Officer at Mainz Biomed.
  • As Mainz Biomed's VP of Commercial Operations, Tarrin will put his in-depth market knowledge to work, creating and implementing sales strategies as well as developing key talents able to elevate customer experiences and drive revenue growth.
  • Commenting on his appointment, Tarrin said, "I am truly excited to join Mainz Biomed and contribute to the ongoing advancement of colorectal cancer screening through ColoAlert®.